Publications by authors named "Arianna E Lofrano"
Background: In this study, we evaluate the previously reported novel Minnesota Score for association with in-hospital mortality and allocation of venovenous extracorporeal membrane oxygenation in patients with acute respiratory distress syndrome with or without SARS-CoV-2 pneumonia.
Methods: This was a retrospective cohort study across four extracorporeal membrane oxygenation centers in Minnesota. Logistic regression was used to assess the relationship between the scores and in-hospital mortality, duration of ECMO cannulation, and discharge disposition.
Objectives: Determine the factors associated with mortality in venovenous extracorporeal membrane oxygenation (V-V ECMO) patients with COVID-19 infection and provide an updated report of clinical outcomes for patients treated with V-V ECMO for COVID-19 in Minnesota.
Design: Multicenter prospective observational study.
Setting: The four adult Extracorporeal Life Support Organization-certified Centers of Excellence in Minnesota.
Article Synopsis
- Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a supportive treatment for adults with severe COVID-19-related ARDS, achieving hospital survival rates of 62%-74%, comparable to other conditions requiring ECMO.
- A study analyzed 46 patients receiving ECMO in Minnesota from March to November 2020, finding that 30 (65.2%) survived for 60 days, with factors such as older age, lower oxygenation levels, and higher organ failure scores linked to higher mortality risk.
- After initiating ECMO, increased mortality was correlated with longer antibiotic use, more blood transfusions, elevated white blood cell counts, and changes in platelet levels, indicating that infections significantly impact survival outcomes
Severe acute respiratory distress syndrome (ARDS) unresponsive to conventional intensive care unit (ICU) management is an accepted indication for venovenous extracorporeal membrane oxygenation (V-V ECMO) support. The frequency with which patients with coronavirus disease 2019 (COVID-19) pneumonia are selected for V-V ECMO has not been described. This was a cohort study including all patients placed on either V-V ECMO or venoarteriovenous ECMO at the four adult ECMO Centers of Excellence.
View Article and Find Full Text PDF